SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below key support levels are dominating discussion, with traders pointing to leveraged-long liquidations and broader risk-off pressure across crypto and tech as possible contributors. The community is split between warnings of further downside and calls to buy an oversold dip or watch for support.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas reiterated that topline results from its Phase 3 REGAL trial of GPS in AML are expected in November after the trial reached its required event milestone, drawing attention to the pending binary readout. Traders are broadly excited about the prospect of positive data and a short squeeze, while speculation about a leak or buyout remains unconfirmed and skeptics stress that results have not been released and the trial outcome is uncertain.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about work interruptions and concern that the prolonged disruption could damage trust or pressure the stock. Some traders speculated about a cyberattack, but the cause was not confirmed, and others questioned why shares held relatively steady.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline toward the $1 support level amid a broader crypto selloff is dominating discussion, with traders pointing to Bitcoin weakness, inflation and rate concerns, and liquidations. Bears warn of further downside and question Ripples ability to provide catalysts, while some holders view the drop as a buying opportunity and continue accumulating.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Weakness in Ethereum and broader crypto-linked stocks is weighing on BitMine, while traders also criticize its underperformance and question managements spending, transparency, and buybacks. Some see the stocks discount to its crypto holdings as a buying opportunity, but bearish posts argue falling ETH prices can overwhelm any support from repurchases.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure as Bitcoin and broader crypto markets sell off, with traders highlighting COINs repeated new lows and weak performance even when Bitcoin stabilizes. Bearish calls dominate, though some see the decline as oversold and are buying the dip.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Decision Watch: What Investors Need To Know About Four Upcoming Drug Rulings

Equity

Investors are set to turn their focus on FDA decisions on experimental treatments for hepatitis B, RRP, sickle cell disease and psoriatic arthritis.


Sun Pharma Considers Debt Swap, Bonds for Mega USD 12 Billion Organon Acquisition: Report

… proposed merger , they added. Separately, the company is planning to raise as much as … would rank among the largest outbound acquisitions by an Indian drugmaker and … multiple aspects and milestones of the acquisition including finalizing the long-term capital …

Indian industry led by pharma to invest $20.5 billion in the US

Includes $1.1 bn announced at SelectUSA 2026 and Sun Pharma’s $11.75 billionn Organon acquisition

Organon Deal: Sun Pharma's Biggest Bet Faces A Growth Test

… of the country’s largest pharmaceutical (pharma ) company, Sun Pharmaceutical Industries, rose 7 per … the largest overseas acquisition by an Indian pharma company. The sharp gains in the stock … of a business spun off from Merck in 2021 offers Sun entry …

India's Sun Pharma buys Organon for $12B boosting specialty portfolio

Sun Pharma , India's biggest … 's lineup, including drugs for breast cancer and women …

THE PHARMA FRONTIER: Sun Pharma’s Global Leap Amidst Market Resilience

Today, Monday, May 4, 2026, the Indian pharmaceutical landscape has reached a historic milestone. While the broader markets showed… Continue reading on Medium »

OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal

OGN stock is on track for a record monthly gain, rising 88% in April, including a 31% surge on Friday, its strongest session ever.

Why Is OGN Stock Rising In Pre-Market Today?

India’s Sun Pharmaceutical Industries submitted a binding $13 billion offer to acquire Organon, according to an Economic Times article on Friday.

OGN Stock Surges 20% Pre-Market, On Track To Break 200-DMA – Why This Buyout Report Has Caught Investor Attention

A report stated that Indian pharmaceutical giant Sun Pharma is expected to submit a $12 billion binding offer for the company.

Breakout Buys: Tata Steel, BSE, Vedanta And Sun Pharma Poised For Upside

These four stocks have shown strong technical setups backed by heavy volumes.


Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

Sun Pharmaceutical Industries Ltd.

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$GSK" data-symbol-id="GSK" href="https://stocktwits.com/symbol/GSK" target="_blank">GSK</a>’s hepatitis B treatment achieved a functional cure in 19% of patients in two late-stage trials.</li><li>Inovio’s therapy reduced the need for repeated surgeries in 81.3% of patients with recurrent respiratory papillomatosis.</li><li>Agios is seeking accelerated approval for Mitapivat for patients aged 16 and older with sickle cell disease.</li></ul>After clearing several new and expanded drug uses last week, most notably ImmunityBio’s (IBRX) Anktiva for an additional form of bladder cancer, all eyes now turn to the U.S. Food and Drug Administration’s (FDA) decisions on drugs to treat hepatitis B, respiratory disease, and sickle cell disease.The momentum continues over the next couple of weeks, with the FDA set to issue decisions on GSK (GSK), Sun Pharmaceutical Industries (SUNPHARMA), Inovio Pharmaceuticals (INO), and Agios Pharmaceuticals (AGIO).<img src="https://news.stocktwits-cdn.com/FDA_Decisions_a4eb0d9031.png" alt="FDA Decisions.png"><h2 class="st-heading-2">FDA’s Verdict On GSK’s Hepatitis B Treatment On Oct. 26</h2>The FDA is likely to announce its decision on GSK’s Bepirovirsen, an experimental treatment for adults with chronic hepatitis B, on October 26. The drug is designed to reduce the production of proteins that allow the virus to multiply and help the immune system control the infection, potentially without the need for continuous treatment.The application is supported by Phase 3 B-Well 1 and B-Well 2 trials, in which 19% of eligible patients receiving Bepirovirsen alongside standard treatment achieved a functional cure, compared with none receiving standard treatment alone. A functional cure means the hepatitis B virus remains suppressed without treatment.Among patients with lower viral activity at the start of the study, the functional cure rate was 26%.The FDA granted the application Priority Review and Breakthrough Therapy designation, as the disease affects about 1.7 million people in the United States, according to GSK.<h2 class="st-heading-2">Inovio’s RRP Therapy In Focus</h2>Investors will then focus on Inovio Pharmaceuticals, whose INO-3107, an experimental treatment for adults with recurrent respiratory papillomatosis (RRP), is expected to receive a regulatory decision on October 30.RRP is a rare disease caused by certain strains of human papillomavirus (HPV), which leads to recurring growths in the respiratory tract. Patients often require repeated surgeries to remove these growths.INO-3107 is designed to help the immune system attack HPV-infected cells. Inovio is seeking an accelerated approval, with the disease reportedly affecting an estimated 14,000 people in the U.S.In a Phase 1/2 study of 32 patients, 81.3% required fewer surgeries in the year following treatment, while 28.1% required no surgeries during or after treatment.<h2 class="st-heading-2">Agios Awaits Decision On Mitapivat</h2>With Mitapivat already approved for certain inherited blood disorders, Agios is now seeking an accelerated approval for patients aged 16 and older with sickle cell disease, which can lead to anemia and potential organ damage. The decision is expected on November 1.The oral drug activates an enzyme called pyruvate kinase, which helps red blood cells produce energy and function more effectively.The Phase 3 Rise Up trial, which involved 207 patients, supports the application. In the study, 40.6% of patients receiving Mitapivat achieved a meaningful increase in hemoglobin levels, compared with 2.9% receiving placebo.Additional analyses also showed that patients receiving Mitapivat were less likely to require blood transfusions.<h2 class="st-heading-2">Sun Pharma Wants To Expand Ilumya’s Use</h2>India-based Sun Pharmaceutical Industries, which recently expanded its U.S. operations with the acquisition of Organon (OGN), is awaiting FDA’s decision on Ilumya, an injectable treatment that is being expanded for the treatment of active psoriatic arthritis.Ilumya works by blocking interleukin-23 (IL-23), a protein involved in inflammation. The drug was first approved in the U.S. in 2018 to treat moderate-to-severe plaque psoriasis.Sun Pharma is seeking approval to expand Ilumya’s use beyond skin symptoms to patients with joint-related disease, with a decision awaited on October 29.<h2 class="st-heading-2">How Have AGIO, INO, GSK And Sun Pharma Performed So Far This Year?</h2>Retail sentiment surrounding AGIO, GSK and INO trended in the ‘bullish’ territory, and ‘neutral’ for Sun Pharma.<img src="https://news.stocktwits-cdn.com/YTD_Biotech_1_f3e6a5a9bc.png" alt="YTD Biotech (1).png">The stocks’ movement so far this year has been mixed, with Agios Pharma gaining 15.2%, while Sun Pharma has risen 1.8%. In contrast, GSK has edged 0.2% lower, while Inovio Pharmaceuticals has plunged 43.4%, the worst performer in this cohort.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/rtx-counter-drone-orders-aerovironment-palantir-defense-ai/cZxjx4bRBtI">&nbsp;Stocktwits Defense Watch: RTX Continues Deal Momentum, Ondas-Palantir Launch AI Firm As AeroVironment Strike Four International Deals</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

GSK’s hepatitis B treatment achieved a functional cure in 19% of patients in two late-stage trials.

Current Price	1,911.00
Prev Close	1,885.00
Open	1,887.00
Dividend Yield	0.91%
50-Day Moving Average	1,816.66
Beta	N/A
Avg. Volume	1.52M
PE Ratio	41.24

52-Week High	2,046.90
52-Week Low	1,583.70
Market Capitalization	4.55T
EPS (Annual)	47.84
Price to Book	5.07
Revenue Per Employee	20.14M

Feed

News

Sentiment

Earnings

Fundamentals

Info

SUNPHARMA.NSE Fundamentals